Political Appointees Shouldn't Influence Approval Decisions, Califf Says
Executive Summary
FDA commissioner offers new details about why he left final decision on Sarepta's controversial Duchenne muscular dystrophy drug to FDA's expert bureaucrats.
You may also be interested in...
Wall Street Sees Woodcock Commissionership As Positive for Aducanumab, But Eyes Should Be On Cavazzoni
Review extension for Alzheimer’s candidate may be positive for Biogen, but it’s not because Woodcock is acting commissioner. To understand the odds, it may be time to get to better know a new generation of US FDA’s drug review leadership.
Gottlieb vs Azar vs Califf vs Gottlieb: The Public Fight Over How The US FDA Should Operate
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.
Gottlieb's Confirmation: Will Industry Ties Remain A Problem After The Hearing?
The US FDA commissioner does not generally get involved with day-to-day activities, former FDA chiefs say, but perception of bias could be a lasting problem.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: